AR and prostate cancer: Using this SARS-CoV-2 bioassay platform, we demonstrated that AR antagonists FDA-approved for prostate cancer treatment (apalutamide, darolutamide, enzalutamide) inhibited SARS-CoV-2 infection in LNCaP cells in a dose-dependent manner, with concentration that inhibits response by 50% (IC50) values of 79, 768, and 90 nM, respectively.